AKT1 and neoplasm: Recent preclinical and clinical studies have demonstrated the potential benefits of combining PI3K inhibitors with EGFR inhibitors in other solid tumours, exhibiting synergistic effects by targeting multiple nodes within the interconnected EGFR/MAPK and PI3K/Akt signalling cascades, disrupting tumour growth and overcoming resistance mechanisms [59,60,61,62].